California objects to 23andMe sale to former CEO, says it would skirt state privacy law
By Ron Leuty,
San Francisco Business Times
| 06. 16. 2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will review the deal.
In an objection filed in U.S. Bankruptcy Court in St. Louis, Bonta's team said the proposed structure of 23andMe's sale to a nonprofit formed by Wojcicki skirts a 2021 state law that would require consumers give their "separate and express" consent before their genetic data and biological samples are transferred or disclosed.
More than 20 states have opposed the sale process due to concerns that consumers' genetic information and other private data would be exposed to uses they didn't agree to when signing up for 23andMe's service. In 23andMe's home state of California, the Genetic Information Privacy Act of 2021 should empower consumers to give proactive approval to transfer their data, the filing states.
23andMe doesn't dispute that the law applies, according to the filing, but fears that compliance would be "too costly" because many Californians would...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
